The estimated Net Worth of Raphael J Mannino is at least $5.54 Million dollars as of 11 September 2017. Raphael Mannino owns over 5,000 units of Matinas Biopharma Inc stock worth over $5,035,837 and over the last 20 years he sold MTNB stock worth over $209,081. In addition, he makes $294,636 as Chief Scientific Officer at Matinas Biopharma Inc.
Sign up
Raphael Mannino MTNB stock SEC Form 4 insiders trading
Raphael has made over 6 trades of the Matinas Biopharma Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of MTNB stock worth $7,050 on 11 September 2017.
The largest trade he's ever made was exercising 60,000 units of Matinas Biopharma Inc stock on 31 January 2008 worth over $97,800. On average, Raphael trades about 6,630 units every 245 days since 2004. As of 11 September 2017 he still owns at least 1,424,565 units of Matinas Biopharma Inc stock.
You can see the complete history of Raphael Mannino stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Raphael Mannino biography
Dr. Raphael J. Mannino Ph.D. serves as Chief Scientific Officer of the Company. Dr. Mannino has served as our Senior Vice President and Chief Scientific Officer since September 2015. From 1990 until August 2015, Dr. Mannino was an Associate Professor of Pathology and Laboratory Medicine at Rutgers University, New Jersey Medical School. Dr. Mannino founded BioDelivery Sciences, Inc., and served as its President, Chief Executive Officer and Chief Scientific Officer and a member of its Board of Directors from 1995 to 2000, when it was acquired by BioDelivery Sciences International, Inc. (NASDAQ: BDSI). Dr. Mannino served as BDSI’s Executive Vice President and Chief Scientific Officer from 2001 to 2009 and a member of its Board of Directors from 2000 to 2007. Dr. Mannino’s previous experience includes positions as Assistant, then Associate Professor, Albany Medical College (1980 to 1990), and Instructor then Assistant Professor, Rutgers Medical School (1977 to 1980). His postdoctoral training was from 1973 to 1976 at the Biocenter in Basel, Switzerland. Dr. Mannino received his Ph.D. in Biological Chemistry in 1973 from the Johns Hopkins University, School of Medicine.
What is the salary of Raphael Mannino?
As the Chief Scientific Officer of Matinas Biopharma Inc, the total compensation of Raphael Mannino at Matinas Biopharma Inc is $294,636. There are 7 executives at Matinas Biopharma Inc getting paid more, with Jerome Jabbour having the highest compensation of $1,325,180.
How old is Raphael Mannino?
Raphael Mannino is 72, he's been the Chief Scientific Officer of Matinas Biopharma Inc since 2018. There are 2 older and 14 younger executives at Matinas Biopharma Inc. The oldest executive at Matinas Biopharma Holdings Inc is Herbert Conrad, 87, who is the Independent Chairman of the Board.
What's Raphael Mannino's mailing address?
Raphael's mailing address filed with the SEC is C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER, NJ, 07921.
Insiders trading at Matinas Biopharma Inc
Over the last 8 years, insiders at Matinas Biopharma Inc have traded over $0 worth of Matinas Biopharma Inc stock and bought 1,157,037 units worth $1,139,222 . The most active insiders traders include Patrick G Lepore, Adam K Stern und James S Scibetta. On average, Matinas Biopharma Inc executives and independent directors trade stock every 40 days with the average trade being worth of $187,938. The most recent stock trade was executed by Adam K Stern on 21 August 2020, trading 20,000 units of MTNB stock currently worth $16,600.
What does Matinas Biopharma Inc do?
matinas biopharma (nyse mkt: mtnb) is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications. the company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. the company's lead drug candidate mat2203, currently in phase 2, is an orally-administered, encochleated formulation of amphotericin b (a broad spectrum fungicidal agent). the company has an open investigational new drug (ind) application for mat2501, currently in phase 1, which is an orally-administered, encochleated formulation of amikacin (a broad spectrum aminoglycoside antibiotic agent) for acute bacterial infections, including non-tuberculous mycobacterium (ntm) and multi-drug resistant gram negative bacterial infections. the company's lead anti-infective product candidates, mat2203 and mat2501, position matinas biopharma to bec
What does Matinas Biopharma Inc's logo look like?
Complete history of Raphael Mannino stock trades at Biodelivery Sciences International und Matinas Biopharma Inc
Matinas Biopharma Inc executives and stock owners
Matinas Biopharma Inc executives and other stock owners filed with the SEC include:
-
Jerome Jabbour,
President, Chief Executive Officer, Director -
Keith Kucinski,
Chief Financial Officer -
James Ferguson,
Chief Medical Officer -
Jerome D. Jabbour J.D.,
Co-Founder, CEO, Pres & Director -
Theresa Matkovits,
Chief Development Officer -
Dr. James J. Ferguson FACC, M.D.,
Chief Medical Officer -
Dr. Theresa Matkovits Ph.D.,
Chief Devel. Officer -
Raphael Mannino,
Chief Scientific Officer -
Ian Cooney,
Director ,Investor Relations & Corporate Development -
Matthew Wikler,
Independent Director -
James Scibetta,
Independent Director -
Natasha Giordano,
Independent Director -
Eric Ende,
Independent Director -
Patrick LePore,
Independent Vice Chairman of the board -
Herbert Conrad,
Independent Chairman of the Board -
Thomas J. Hoover M.B.A.,
Chief Bus. Officer -
Frank Calamusa,
Exec. Director and Head of Manufacturing & Supply Chain -
Dr. Raphael J. Mannino Ph.D.,
Chief Scientific Officer -
Dr. Hui Liu M.B.A., Ph.D.,
Chief Technology Officer -
Keith A. Kucinski CPA, M.B.A.,
Chief Financial Officer -
Adam K Stern,
Director -
Dominick Di Paolo,
Senior VP of Compliance -
Gary Gaglione,
Chief Financial Officer -
Roelof Rongen,
Chief Executive Officer -
Jennifer Gjg Life Sciences,...,
-
Stefano Ferrari,
Director -
Hui Liu,
Chief Technology Officer -
Kathryn Penkus Corzo,
Director -
Thomas Hoover,
Chief Business Officer